Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C

American Journal of Medicine

Volumn 108, Issue 5, 2000, Pages 366-373

  Wong, John B ^a   Davis, Gary L ^b   Pauker, Stephen G ^a  

^a Tupper R   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEPATITIS C; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIFE EXPECTANCY; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0034177475     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00303-X     Document Type: Article

References (65)

1. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997;26(suppl 1):2S-10S.
2. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States 1988 through 1994. NEJM. 341:1999;556-562.
3. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 47:1998;1-39.
4. Poynard T., Leroy V., Cohard M., et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C effects of dose and duration . Hepatology. 24:1996;778-789.
5. Carithers R.L. Jr, Emerson S.S. Therapy of hepatitis C meta-analysis of interferon alfa-2b trials . Hepatology. 26:1997;83S-88S.
6. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. NEJM. 339:1998;1493-1499.
7. Bennett W.G., Inoue Y., Beck J.R., et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 127:1997;855-865.
8. Kim W.R., Poterucha J.J., Hermans J.E., et al. Cost-effectiveness of 6, and 12 months of interferon-a therapy for chronic hepatitis C. Ann Intern Med. 127:1997;866-874.
9. Wong J.B., Bennett W.G., Koff R.S., Pauker S.G. Pre-treatment evaluation of chronic hepatitis C risks, benefits and costs . JAMA. 280:1998;2088-2093.
10. Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 15:1997;110-115.
11. Heckerling P.S., Verp M.S. Amniocentesis or chorionic villus sampling for prenatal genetic testing a decision analysis . J Clin Epidemiol. 44:1991;657-670.
12. Kuppermann M., Shiboski S., Feeny D., et al. Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Med Decis Making. 17:1997;42-55.
13. 1999 Drug Topics Red Book. 1999;Medical Economics Data, Montvale, NJ.
14. St. Anthony's DRG Guidebook 1995. Alexandria, Vir: St. Anthony Publishing; 1996.
15. Ashraf T., Arnold S.B., Maxfield M. Cost-effectiveness of levonorgestrel subdermal implants. Comparison with other contraceptive methods available in the United States. J Reprod Med. 39:1994;791-798.
16. Wasserman Y. Physicians' Fee Reference 1995. 1995;Medical Publishers, Ltd, West Allis, Wisconsin.
17. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York.
18. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
19. Desmet V.J., Gerber M., Hoofnagle J.H., et al. Classification of chronic hepatitis diagnosis, grading, and staging . Hepatology. 19:1994;1513-1520.
20. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 349:1997;825-832.
21. Yano M., Kumada H., Kage M., et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 23:1996;1334-1340.
22. Tong M.J., Blatt L.M., McHutchison J.G., et al. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics a comparison . Hepatology. 26:1997;1640-1645.
23. Bonis P.A., Ioannidis J.P., Cappelleri J.C., et al. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C a meta-analysis of diagnostic test characteristics . Hepatology. 26:1997;1035-1044.
24. Reichard O., Glaumann H., Fryden A., et al. Two-year biochemcial, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 21:1995;918-922.
25. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
26. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. NEJM. 339:1998;1485-1492.
27. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan . Ann Intern Med. 131:1999;174-181.
28. Hoofnagle J.H. Hepatitis C the clinical spectrum of disease . Hepatology. 26:1997;15S-20S.
29. Bennett W.G., Pauker S.G., Davis G.L., Wong J.B. Modeling therapeutic benefit in the midst of uncertainty therapy for hepatitis C . Dig Dis Sci. 41:1996;56S-62S.
30. Heathcote E.J., Keeffe E.B., Lee S.S., et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology. 27:1998;1136-1143.
31. Jacobson IM. Update on combination therapy in relapsers following interferon. Clinician's Companion Development Meeting, Laguna Niguel, California, 1999.
32. Rabeneck L. Surrogates, survival, and subversion. Hepatology. 26:1997;1678-1679.
33. Koretz R.L. Interferon and hepatocellular carcinoma. Lancet. 347:1996;194.
34. Harper S.E., Dienstag J.L. Can interferon alfa treatment prevent hepatocellular carcinoma in patients with chronic hepatitis C infection and compensated cirrhosis? Hepatology. 23:1996;930-933.
35. Grimm I., Shaheen N. Can interferon prevent hepatocellular carcinoma in hepatitis C virus-induced cirrhosis? Gastroenterology. 110:1996;2019-2021.
36. Poynard T., Opolon P. Hepatitis C somber views of natural history and optimistic views of interferon treatment? Hepatology. 27:1998;1443-1444.
37. Poynard T., Moussalli V., Ratziu V., et al. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Acta Gastro-Enterologica Belgica. 59:1998;431-437.
38. Niederau C., Lange S., Heintges T., et al. Prognosis of chronic hepatitis C results of a large, prospective cohort study . Hepatology. 28:1998;1687-1695.
39. Fattovich G., Giustina G., Degos F., et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 27:1997;201-205.
40. Valla D.C., Chevallier M., Marcellin P., et al. Treatment of hepatitis C-related cirrhosis a randomized, controlled trial of interferon alfa-2b versus no treatment . Hepatology. 29:1999;1870-1875.
41. Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement, and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C, and sustained response to interferon-alpha therapy. Ann Intern Med. 127:1997;875-881.
42. Camma C., Giunta M., Linea C., Pagliaro L. The effect of interferon on the liver in chronic hepatitis C a quantitative evaluation of histology by meta-analysis . J Hepatol. 26:1997;1187-1199.
43. Teramura K., Fukuda A., Kobayashi H., et al. Virus elimination and histologic improvement in patients with chronic hepatitis C treated with interferon alpha. J Clin Gastroenterol. 25:1997;346-351.
44. Lau D.T., Kleiner D.E., Ghany M.G., et al. 10-year follow-up after interferon-alfa therapy for chronic hepatitis C. Hepatology. 28:1998;1121-1127.
45. Sobesky R., Mathurin P., Charlotte F., et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C a dynamic view. The Multivirc Group . Gastroenterology. 116:1999;378-386.
46. Reichard O., Glaumann H., Fryden A., et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol. 30:1999;783-787.
47. Shindo M., Ken A., Okuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer. 85:1999;1943-1950.
48. Nishiguchi S., Kuroki T., Nakatani S., et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.
49. Mazzella G., Accogli E., Sottili S., et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 24:1996;141-147.
50. Kuwana K., Ichida T., Kamimura T., et al. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma a multivariate analysis in 343 patients . J Gastroenterol Hepatol. 12:1997;149-155.
51. Imai Y., Kawata S., Tamura S., et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 129:1998;94-99.
52. Kasahara A., Hayashi N., Mochizuki K., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 27:1998;1394-1402.
53. Benvegnu L., Chemello L., Noventa F., et al. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer. 83:1998;901-909.
54. Ikeda K., Saitoh S., Arase Y., et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis . Hepatology. 29:1999;1124-1130.
55. Serfaty L., Aumaitre H., Chazouilleres O., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 27:1998;1435-1440.
56. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma a retrospective cohort study . Lancet. 251:1998;1535-1539.
57. Seeff L.B. Natural history of hepatitis C. Hepatology. 26:1997;21S-28S.
58. Sackett D.L., Torrance G.W. The utility of different health states as perceived by the general public. J Chron Dis. 31:1978;697-704.
59. Boyd N.F., Sutherland H.J., Heasman K.Z., et al. Whose utilities for decision analysis? Med Decis Making. 10:1990;58-67.
60. Finkler S.A. The distinction between cost and charges. Ann Intern Med. 96:1982;102-109.
61. Ellwein L.B., Drummond M.F. Economic analysis alongside clinical trials. Bias in the assessment of economic outcomes. Int J Te A. 12:1996;691-697.
62. Drummond M.F., Davies L. Economic analysis alongside clinical trials. Revisiting the methodological issues. Int J Te A. 7:1991;561-573.
63. Wright J.C., Weinstein M.C. Gains in life expectancy from medical interventions. Standardizing data on outcomes. NEJM. 339:1998;380-386.
64. Tsevat J., Weinstein M.C., Williams L.W., et al. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation. 83:1991;1194-1201.
65. Wong J.B., Koff R.S., Tine F., Pauker S.G. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 122:1995;664-675.